Cardiac resynchronization therapy for the treatment of sleep apnoea: a meta-analysis

Aims Sleep apnoea (SA) is a common problem among congestive heart failure (CHF) patients. Evidence has shown that cardiac resynchronization therapy (CRT) reduces morbidity and mortality associated with CHF. The aim of this paper was to review studies evaluating the reduction of the Apnoea-Hypopnoea Index (AHI) in patients with SA after treatment with CRT and to perform a meta-analysis to estimate the true effect of CRT on SA. Methods and results A systematic electronic literature search was conducted in Medline and Embase to identify studies reporting on the effects of CRT on SA. A hand search of five major cardiology societies was performed to identify any unpublished studies through structured abstracts submitted to conference proceedings. To be eligible for inclusion, studies had to include a comparison of CRT vs. no pacing and use AHI as an outcome. Non-English studies were excluded. Nine manuscripts and five abstracts were identified for review. Six manuscripts and three abstracts were included in meta-analysis, which included 170 patients. After treatment with CRT, a significant reduction in AHI was found in patients with central sleep apnoea (CSA) with a mean reduction of 213.05 (CI -16.74 to -9.36; P < 0.00001) but not in patients with obstructive sleep apnoea (13.32; CI -9.04 to 2.39; P = 0.25). Conclusion Cardiac resynchronization therapy reduces the severity of SA. Major effects are seen in patients with CSA. The presence of SA may be an additional consideration when deciding on which heart failure patients will receive CRT.